MedImmune Cambridge is a leading biopharmaceutical operation committed to developing human monoclonal antibody therapeutics to bring improvements to seriously ill patients' lives. Our world-leading, proprietary Phage Display and Ribosome Display technologies form the basis of our strategy to develop a portfolio of human monoclonal antibody therapeutics.

Following the recent announcement of a non-exclusive licence agreement with Regeneron, MedImmune will be combining Regeneron’s VelocImmune^® technology with its proprietary Display technologies, extending further the company’s industry-leading biologics platform.